In this article, we will discuss Palbociclib (Dosage Overview). So, let’s get started.
Palbociclib (IBRANCE®) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or
• fulvestrant in patients with disease progression following endocrine therapy.
Recommended Dose and Schedule
The recommended dose of Palbociclib (IBRANCE®) is a 125 mg tablet taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib (IBRANCE®) tablet may be taken with or without food.
Administer the recommended dose of an aromatase inhibitor when given with Palbociclib (IBRANCE®).
When given with Palbociclib (IBRANCE®), the recommended dose of fulvestrant is 500 mg administered on Days 1, 15, 29, and once monthly thereafter.
Patients should be encouraged to take their dose of Palbociclib (IBRANCE®) at approximately the same time each day. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.
Pre/perimenopausal women treated with the combination Palbociclib (IBRANCE®) plus fulvestrant therapy should also be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.
For men treated with combination Palbociclib (IBRANCE®) plus aromatase inhibitor therapy, consider treatment with an LHRH agonist according to current clinical practice standards.
Most common adverse reactions (incidence ≥10%) were neutropenia,
infections, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, vomiting, decreased appetite, asthenia, and